MAPT and Alzheimer disease: Given that fully automated immunoassay has low analytical variability in the CRM-adjusted CSF AD biomarker levels compared with manual immunoassay [14], comparing the discrepancy in the Aβ42 level or tau proteins measured by Lumipulse in our study with other studies may be due to clinical variables or pre-analytics.